Soligenix (NASDAQ:SNGX) Releases Quarterly Earnings Results, Beats Estimates By $0.43 EPS

Soligenix (NASDAQ:SNGX) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported $0.16 EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.43, FiscalAI reports.

Soligenix Stock Performance

Shares of SNGX stock traded up $0.07 during mid-day trading on Tuesday, hitting $1.18. 201,944 shares of the stock traded hands, compared to its average volume of 336,732. Soligenix has a twelve month low of $1.00 and a twelve month high of $6.23. The company’s 50-day simple moving average is $1.19 and its 200-day simple moving average is $1.42. The firm has a market cap of $11.91 million, a price-to-earnings ratio of -0.33 and a beta of 1.99.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Banco BTG Pactual S.A. acquired a new stake in shares of Soligenix during the third quarter valued at approximately $54,000. Virtu Financial LLC acquired a new position in Soligenix in the 3rd quarter worth approximately $59,000. XTX Topco Ltd purchased a new position in Soligenix during the 4th quarter worth approximately $37,000. Armistice Capital LLC acquired a new stake in Soligenix during the 3rd quarter valued at $821,000. Finally, Geode Capital Management LLC raised its stake in Soligenix by 88.8% during the 4th quarter. Geode Capital Management LLC now owns 80,401 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 37,811 shares during the period. 3.60% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $6.00.

About Soligenix

Soligenix, Inc is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.